Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth

Group 1 - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is currently viewed as a strong investment opportunity despite recent price target reductions by analysts [1][2] - Morgan Stanley lowered its price target for Alnylam from $408 to $360 while maintaining an Equal Weight rating, citing near-term pressures but increased confidence in the company's revenue and sales guidance for 2026 [1] - RBC Capital also reduced its price target from $465 to $450 but kept an Outperform rating, recognizing Alnylam's strong commercial execution and potential to meet financial targets [2] Group 2 - Alnylam has a significant market opportunity with 80% of the 300,000 global TTR-CM patients remaining undiagnosed, which the company aims to address [4] - The company is expanding its focus beyond the TTR franchise to include treatments for Huntington's disease, obesity, and HHT, indicating a strategy for growth [4] - Alnylam specializes in RNAi therapeutics and offers solutions for various conditions, including hypercholesterolemia and acute hepatic porphyria, showcasing its diverse therapeutic portfolio [5]